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Abstract
The use of proton therapy in oncology is not a new idea. The unique physical 
properties of protons and potential advantages in radiation therapy were initially rec-
ognized in the 1940s. Since the first patients were treated in the 1950s, technology and 
clinical applications have evolved as evidenced by the increasing number of proton 
therapy centers and patients being treated throughout the world. This chapter will 
review the history of proton therapy providing a detailed overview of the cyclotron 
and synchrotron techniques used and how they have advanced with time.
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1. Introduction
Radiation therapy is a standard local treatment in oncology with nearly 50% of 
cancer patients receiving radiation at some point in their disease course [1, 2]. This 
is most often used in combination with surgery, chemotherapy and, more recently, 
immunotherapy [3, 4]. The underlying principle of using ionizing radiation in 
oncology is based on its transfer of energy to tissues resulting in DNA damage, 
the acquisition of mutations that disrupt cell physiology and cell death [5, 6]. 
Determining the optimal radiation delivery modality, dose, treatment strategy and 
combination of other therapies have been an active area of investigation for decades 
[7, 8]. Advances in physics, radiology and radiobiology have allowed the field of 
radiation oncology to evolve resulting in more favorable clinical responses while 
minimizing toxicity to normal structures [9].
Several discoveries near the end of the 19th century gave birth to the discipline 
of radiation sciences. At Würzberg University in Germany, Wilhelm Conrad 
Roentgen’s experiments using a cathode-ray tube led to the discovery of x-rays. 
His seminal findings that a “ray” can pass through most solid objects, but not 
bone or metal is, of course, still a central tenet in radiology practice today. The 
discovery of radioactivity by Henri Becquerel and identification of polonium and 
radium by Marie Curie soon followed that resulted in scientific advances that 
would lead to a new era bridging the gap between modern technology and medical 
sciences [10].
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The discoveries made by Roentgen, Becquerel and Curie laid the groundwork for 
industries in healthcare to begin the production of devices to generate high-energy 
beams for diagnostic and therapeutic purposes throughout the early to mid-20th 
century. The roots of proton therapy can be traced to these initial technological 
undertakings [11]. In more recent years, radiation oncology entered a new era with 
the advent of three-dimensional (3D) treatment planning systems. This allowed 
physicians, physicists and dosimetrists to computationally derive solutions to prior 
limitations in external beam radiation therapy planning. Intensity modulated radia-
tion therapy is one such fundamental advance that optimizes conformal radiation 
delivery to a 3D target volume [12]. This widespread use of conformal radiation 
therapy with a focus on increasing tumor cell effect has revamped interest in the 
applications of proton therapy in oncology [13].
For this reason, this chapter will review the history and evolution of proton 
therapy to provide a framework for the later discussion of treatment planning, 
efficacy and future directions.
2. Proton discovery
Atoms are comprised of subatomic particles with a unit positive charge 
(protons), negative charge (electrons) and neutral charge (neutrons). Ernest 
Rutherford’s initial studies on subatomic particles found that α and β rays derived 
from uranium and helium atoms consist of nuclei of α rays. These findings were 
substantial because they led to studies that revealed that when nitrogen gas is irradi-
ated by an α particle it produces oxygen atoms and the nuclei of hydrogen atoms, 
which have a net positive charge. This unit with a net positive charge was termed 
the proton. Rutherford concluded that a nitrogen atom is composed of positively 
charged protons and negatively charged electrons, and that a nitrogen atom can be 
converted to oxygen and a proton (hydrogen atom nucleus) [14, 15]. Following the 
discovery of the proton, James Chadwick at Lawrence Berkeley Laboratory discov-
ered the neutron and studies subsequently began assessing potential applications of 
fast neutron radiation therapy [16–18].
3. Protons vs. photons
Photons are high-energy x-rays and are the traditional modality used in 
external beam radiation therapy. Photon therapy typically relies on several beam 
directions to achieve a uniform dose distribution to a target volume in order to 
treat disease and minimize toxicity to structures at risk. This is because, within 
tissues, photons exhibit a decreasing energy deposition with higher depth. Proton 
therapy, a form of charged-particle therapy, differs from photon therapy regarding 
energy transfer within tissues as proton velocity is inversely proportional to the 
energy transferred within tissues [19]. Therefore, by reducing their velocity based 
on electromagnetic interactions with atoms in tissue, the higher energy they can 
transfer to a pre-determined depth.
This concept of a “peak” was initially discovered by William Bragg in the early 
1900’s and is known as the “Bragg peak.” The Bragg peak, or energy deposition as 
a function of tissue depth, has potential to deliver higher doses to a target volume 
while maintaining dose-constraints of nearby critical structures [20]. The potential 
for increased tumor cell effect while reducing dose to structures at risk is one of the 
underlying factors in the medical interest of proton therapy.
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4. Early stages of proton therapy in medicine
In 1946, Robert Wilson was the first to recognize the potential medical applica-
tions of proton therapy [21]. By utilizing the concept of the Bragg peak and knowl-
edge that protons exhibit decreasing velocity as they travel through tissue, Wilson 
postulated that these physical properties could be advantageous for targeting disease 
deep within healthy tissue. Needless to say, his idea was well ahead of the time. 
Wilson stated,
“These properties make it possible to irradiate intensely a strictly localized region 
within the body, with but little skin dose. It will be easy to produce well collimated 
narrow beams of fast protons, and since the range of the beam is easily controllable, 
precision exposure of well-defined small volumes within the body will soon be 
feasible” [21].
Of course, Wilson highlighted concepts that are still fundamental in the modern 
practice of radiation oncology.
In 1954, the first patients were treated at Lawrence Berkeley Laboratory with 
proton therapy using a cross-firing technique with a 340 MeV proton beam [22]. 
The target was the pituitary gland for hormone suppression in patients with meta-
static breast cancer. In these patients, the Bragg peak was not used due to difficulties 
in approximating the range. This technique was able to concentrate the dose to the 
pituitary with a single-fraction. In 1958, a three-fraction schedule was utilized for 
pituitary radiation [23].
The Gustav Werner Institute in Uppsala, Sweden was the first to incorporate the 
Bragg peak and concepts proposed by Robert Wilson into proton therapy studies. 
A 185 MeV cyclotron was used to treat the initial set of patients in the late 1950s to 
early 1960s, which included work by stereotactic radiosurgery pioneer Lars Leksell 
[24–27]. Interestingly, high doses per fraction were used due to time constraints 
at the cyclotron. The spread-out Bragg peak with a rotating technique was used in 
order to produce range-modulated beams [28, 29]. Together, the use of protons as 
a “neurosurgical tool” for “cerebral surgery” was used to treat dozens of patients 
during this time [30]. The applications of delivering larger doses of intracranial 
radiation to precisely defined targets are still prominent today. The innovation 
of Larsson, Leksell and others is best demonstrated by quoting their 1958 Nature 
article that says,
“with high-energy protons a sharply delimited lesion can be made at any desired 
site in the central nervous system” [30].
In collaboration with Massachusetts General Hospital, the Harvard Cyclotron 
Laboratory launched their program in the 1960s using a 160 MeV cyclotron also 
incorporating the Bragg peak proposed by Wilson [31]. Again, neurological targets 
were identified for radiosurgery, with a focus on pituitary irradiation [32]. Patients 
with conditions such as acromegaly and Cushing’s disease had their skull placed 
in a head frame in order to target the “beam spot” within the sella turica [32]. The 
authors reported satisfactory results, which included the reduction of complications 
with added experience. Their success gained recognition and received funding by 
agencies such as the National Cancer Institute.
In the early 1970s, the Department of Radiation Oncology at Massachusetts 
General Hospital expanded proton therapy to patients with sarcoma, head and 
neck cancer and melanoma [33–35]. In 1979, another oncologic advance developed 
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by this department was the idea of the use of proton therapy for men with prostate 
cancer [36]. Seventeen men with localized prostate cancer were treated with boost 
proton therapy. During the 12 to 27-month follow-up, 16 of these patients were 
locally controlled. In general, side-effects were mild, which included urethral 
stricture in two patients. Minimal rectal toxicity was reported in follow-up.
Throughout the 1970s, Russia initiated several proton therapy programs. These 
occurred at several institutions including the Joint Center for Nuclear Research, 
the Institute of Theoretical and Experimental Physics and a collaboration between 
the Petersburg Nuclear Physics Institute and the Central Research Institute of 
Roentgenology and Radiology. The Institute of Theoretical and Experimental 
Physics was the largest of these programs [37], which used a 7.2 GeV proton 
synchrotron. Using the Bragg peak, pituitary irradiation of breast and prostate 
cancer patients was performed. By 1981, nearly 600 patients with breast and 
prostate cancer as well as others with bone metastases, lymph node malignancies, 
osteosarcoma, melanoma, cervical cancer and eye tumors were treated [37, 38]. 
This expanded the applications of proton therapy not only for pituitary irradiation, 
but for several extracranial conditions.
Although Japan is a large user of proton therapy today [39], they had only 
treated 11 patients with proton therapy alone and 18 patients with a proton boost 
into the early 1980s [40]. Their efforts took place at the National Institute of 
Radiological Sciences in Chiba and subsequently at the Particle Radiation Medical 
Science Center in Tsukuba. Since that time, proton therapy has greatly expanded in 
Japan with more than 10 centers available for treating patients [39].
5. Expansion of proton therapy
Throughout the 1980s, proton therapy was primarily used for intracranial 
stereotactic radiosurgery [41]. However, clear advantages of proton therapy were 
demonstrated in treating patients with conditions with otherwise limited thera-
peutic options such as chondroma and choroidal melanoma [42–44]. While proton 
therapy centers had provided benefit to many patients throughout the world, in the 
1970s and 1980s, a severe limitation was that they were located at research institu-
tions. This limited the number of patients being treated since these centers had 
several ongoing research projects that required beam time. Moreover, it inconve-
nienced both the medical team and patients due to the requirement to travel to the 
research centers for treatment.
In 1990, the first proton therapy center based out of a hospital was built at the 
Loma Linda University Medical Center [45]. This was an undertaking that required 
Fermilab to develop the synchrotron and the Harvard Cyclotron Laboratory to 
design the gantries. Soon after its implementation, Loma Linda University Medical 
Center established itself as a leader in proton therapy. The large number of patients 
treated during the 1990s at Loma Linda provided evidence that proton therapy had 
the potential to be an important modality in radiation oncology. Since its operation 
began, Loma Linda University Medical Center has remained a prominent proton 
therapy institute and research center [46].
Following the initial success of Loma Linda University Medical Center, the 
proton therapy center at the Harvard Cyclotron Laboratory was transferred to the 
Massachusetts General Hospital for clinical use in 2001. Around this time, Indiana 
University also implemented a hospital-based proton therapy center. This increase 
in hospital-based proton therapy centers and technological advances allowed 
radiation oncology departments to recognize the possibility of widespread use that 
5
History and Overview of Proton Therapy
DOI: http://dx.doi.org/10.5772/intechopen.95959
could lead to continued advances in clinical settings. This is evidenced by a drastic 
increase over time in the number of proton therapy facilities worldwide [47].
6. Evolution of proton therapy technology
As detailed above, initial proton therapy centers utilized a cyclotron, which 
circulates particles using an electromagnetic field and accelerates them based on 
an energy selection system [48]. This process continually produces a single batch 
of protons. The major advance of synchrotron systems was the ability to accelerate 
particles of different energy levels, which produces pulses of protons and results in 
a more energy efficient process [48].
Initially, cyclotron and synchrotron systems produced beams the width of a 
“pencil”, which made treating larger targets difficult. Thus, scattering foils were 
used to broaden beam width. However, use of a single scattering foil was insuf-
ficient due to limitations in achieving reproducible beam flatness. In the late 
1970s, the double scattering system was incorporated at the Harvard Cyclotron 
Laboratory, which could accurately reproduce beam flatness to homogenously 
cover larger treatment volumes [49]. This required materials with specific physical 
properties to ensure a beam of desired width [50].
At the Gustav Werner Institute in Uppsala, Sweden, Larsson introduced the 
concept of magnetic beam scanning to replace the previously used scattering 
techniques [25]. Many types of magnetic beam scanning techniques have been 
proposed. Initially, spot scanning was developed, but 3D continuous scanning soon 
became widely used. Technological advances in 3D beam scanning techniques were 
later developed that produced more conformal beams that were highly effective at 
reducing the dose to structures at risk [51]. As the advent of intensity modulated 
radiation therapy changed the modern practice of radiation oncology, intensity 
modulated proton therapy has become increasingly used at proton centers. The 
physical properties of protons and ability to modulate dose along the beam axis has 
highlighted the advantages of intensity modulated proton therapy and its ability to 
improve tumor cell effect while sparing structures at risk when compared to photon 
therapy [52].
7. Conclusion
The advantages of proton therapy were recognized early in its history by Wilson 
as well as the early treatment centers at Lawrence Berkeley Laboratory, the Gustav 
Werner Institute and the Harvard Cyclotron Laboratory. Since proton therapy is 
particularly attractive for cases where there is a risk of important structures being 
irradiated, intracranial targets, such as the pituitary gland, were the first to be 
treated [22, 23]. This evolved from single fraction to multiple fraction treatments 
[23]. The benefits of sparing nearby, sensitive structures were later highlighted 
by treating chondroma and choroidal melanomas [35, 42–44]. In fact, these 
became some of the most commonly treating conditions at the Harvard Cyclotron 
Laboratory.
Proton therapy has demonstrated more favorable dose distributions when 
compared to photon therapy in several tumor types [53–55]. However, it is unclear 
if these superior dose distributions will translate to better outcomes and, if so, the 
patients who would receive the most benefit will need to be identified. Moreover, 
hospital facilities will need to weigh these potential benefits with the financial and 
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space requirements of a proton beam. Although there is strong evidence for advan-
tages in pediatric patients [56], there continues to be debate in other diseases such 
as prostate cancer [57]. Clinical trials are ongoing to identify the optimal radiation 
modality in various clinical scenarios [58].
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